Segall Bryant & Hamill LLC Invests $2.13 Million in LivaNova PLC (NASDAQ:LIVN)

Segall Bryant & Hamill LLC bought a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 40,477 shares of the company's stock, valued at approximately $2,127,000. Segall Bryant & Hamill LLC owned about 0.07% of LivaNova at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Arizona State Retirement System boosted its stake in LivaNova by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company's stock valued at $828,000 after purchasing an additional 299 shares during the period. Atria Investments Inc boosted its position in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company's stock worth $297,000 after buying an additional 331 shares during the period. Fifth Third Bancorp grew its holdings in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after buying an additional 332 shares in the last quarter. Hexagon Capital Partners LLC increased its position in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock valued at $37,000 after acquiring an additional 370 shares during the period. Finally, State of Alaska Department of Revenue increased its position in LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock valued at $328,000 after acquiring an additional 425 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $75.00 price target on shares of LivaNova in a research report on Tuesday, November 12th. StockNews.com lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. The Goldman Sachs Group started coverage on shares of LivaNova in a research report on Friday, October 4th. They set a "buy" rating and a $65.00 price target on the stock. Mizuho reduced their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. Finally, Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $69.17.

LivaNova Price Performance

Shares of NASDAQ LIVN traded down $0.38 during midday trading on Friday, reaching $51.32. The company's stock had a trading volume of 400,585 shares, compared to its average volume of 567,618. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The company has a market cap of $2.79 billion, a price-to-earnings ratio of 122.19 and a beta of 1.01. The company has a 50 day moving average price of $52.13 and a 200 day moving average price of $52.52. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.